Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company

Merck Boosts Global Distribution Capabilities with €180 Million Expansion of German Center

Fineline Cube Jun 11, 2024

Merck KGaA (ETR: MRK), the German life science and technology company, announced last week a...

Company Drug

Gilead’s Bulevirtide-PegIFN Combo Achieves High HDV Remission Rates in Phase IIb Trial

Fineline Cube Jun 11, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company at the forefront of HIV and liver...

Company Drug

AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC

Fineline Cube Jun 11, 2024

AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that...

Company Deals

MSD Makes Undisclosed Equity Investment in Cancer Diagnostics Firm DELFI Diagnostics

Fineline Cube Jun 7, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics,...

Company Deals

GSK Finalizes Acquisition of Oligonucleotide Specialist Elsie Biotechnologies for Up to $50 Million

Fineline Cube Jun 7, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has announced the completion of the...

Policy / Regulatory

Four More Chinese Provinces Include ART in Medical Insurance Payment System

Fineline Cube Jun 7, 2024

The provincial governments of Jiangxi, Shanghai, Qinghai, and Zhejiang have added assisted reproductive technology (ART)...

Company Legal / IP

J&J Loses US Court Case Over Asbestos in Cosmetic Products; Ordered to Pay $260 Million

Fineline Cube Jun 7, 2024

Johnson & Johnson (J&J; NYSE: JNJ) suffered a defeat in a US court this week,...

Company

MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President

Fineline Cube Jun 7, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as...

Policy / Regulatory

China Unveils Ambitious 2024 Medical Reforms with Increased Investment and Policy Reforms

Fineline Cube Jun 7, 2024

The State Council has issued a notification outlining key medical system reforms for 2024, aiming...

Company

Sinovac Biotech Commits USD 100 Million Investment in Brazil for Vaccine Research and Collaboration

Fineline Cube Jun 7, 2024

Sinovac Biotech Ltd. (NASDAQ: SVA), a leading vaccine specialist based in China, is reportedly set...

Company Medical Device

Sansure Biotech’s HBV RNA Detection Kit Receives NMPA Marketing Approval

Fineline Cube Jun 7, 2024

Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...

Company Medical Device

MicroPort Endovascular MedTech Secures NMPA Approval for Vena Cava Filter

Fineline Cube Jun 7, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...

Company Drug

Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment

Fineline Cube Jun 7, 2024

Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...

Company Drug

Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis

Fineline Cube Jun 7, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Drug

Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan

Fineline Cube Jun 7, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Drug

HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies

Fineline Cube Jun 7, 2024

HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...

Company Deals

Alphamab Oncology Partners with ArriVent BioPharma for Global ADC Development and Commercialization

Fineline Cube Jun 6, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research...

Company Drug

Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting

Fineline Cube Jun 6, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...

Company Drug

Jiangsu Hengrui’s HER2 Targeted ADC SHR-A1811 Poised to Earn Breakthrough Designation in China

Fineline Cube Jun 6, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

3SBio Secures Exclusive Licensing Agreement for Seven Drug Candidates from Subsidiary

Fineline Cube Jun 6, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has disclosed...

Posts pagination

1 … 401 402 403 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.